Long-Term Outcomes in Patients Undergoing Coronary Stenting on Dual Oral Antiplatelet Treatment Requ...
Download
1 / 14

American Journal of Cardiology 2008; 102: 1618-1623 - PowerPoint PPT Presentation


  • 102 Views
  • Uploaded on

Long-Term Outcomes in Patients Undergoing Coronary Stenting on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' American Journal of Cardiology 2008; 102: 1618-1623' - quinlan-mendoza


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Long-Term Outcomes in Patients Undergoing Coronary Stenting on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy

R. Rossini, G. Musumeci, C. Lettieri*, M. Molfese**, L. Mihalcsik, P. Mantovani**, V. Sirbu, T. A. Bass***, F. Della Rovere**, A. Gavazzi, D. J Angiolillo***

Dipartimento Cardiovascolare, Ospedali Riuniti di Bergamo

*Ospedale Carlo Poma, Mantova

**Ospedale Galliera, Genova

*** University of Florida, Jacksonville, US

American Journal of Cardiology 2008; 102: 1618-1623


Background

Background on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy

In patients undergoing coronary stenting, long-term dual antiplatelet therapy with aspirin and clopidogrel reduces atherothrombotic events but also increases the risk of bleeding. The potential for developing bleeding complications is further enhanced in patients also requiring oral anticoagulant treatment (“triple therapy”).


Aim on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy

To assess long-term outcomes associated with the use of triple-therapy in patients undergoing coronary stenting and evaluate how these may be affected by targeting international normalized ratio (INR) values to the lower therapeutic range.


Methods on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy

  • We analyzed 102 consecutive patients undergoing coronary stenting treated with dual antiplatelet therapy also requiring oral anticoagulation. The target international normalized ratio (INR) value was 2-2.5

  • An age and sex-matched control group (n=102) with similar disease presentation and procedure type was selected from the study period

  • 18 months Follow-up:

  • TIMI major and minor bleedings

  • MACE: death, myocardial infarction, stent thrombosis, stroke and target vessel revascularization


Baseline Characteristics on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy

Triple

Controls

P value

( n = 102 )

( n = 102 )

68.2  8.1 0.2

81 (79.4 %) 0.8

46 (45 %) 0.6

35 (34.3 %) 0.9

1.5±0.9 0.8

49 (48%) 0.4

  • Age (y) 67.9  9.3

  • Male 82 (80.4%)

  • UA/NSTEMI 45 (44.1 %)

  • STEMI 35 (34.3 %)

  • Stent/Pt 1.5±0.7

  • Pt with DES 48 (47%)

  • Target INR value 2-2.5


Main Indications for Warfarin use on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy

Mean duration of triple therapy was 158 days (range 30-540)

%


Results: 18-month Major and Minor Bleeding on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy

%

P=0.1

P=0.6

Mean INR at the time of bleeding was 3.1±0.7


Specificity

  • The optimal ROC-defined INR value cut point between sensitivity and specificity for all bleeding was 2.6.

  • This cut-off value had a specificity of 89%, a sensitivity of 66%, a negative predicted value of 95%, and a positive predictive value of 44%.


All bleeding cumulative distribution Specificity

%

100

95.1 %

90

89.2 %

P=0.13

80

Bleeding event free survival

70

Double therapy

60

Triple therapy

50

0

200

300

450

600

Days


All bleeding cumulative distribution by INR Specificity

%

100

95.1 %

95.1 %

90

80

Bleeding event free survival

70

Double therapy

66.7 %

60

Triple therapy with INR < 2.6

Triple therapy with INR ≥ 2.6

50

0

200

300

450

600

Days

† P<0.0001 vs Double therapy

‡ P<0.0001 vs Triple with INR <2.6


  • In the triple therapy group, use of SpecificityGPIIb/IIIa blocker (OR 2.7, P = 0.03), value of INR > 2.6 (OR 9.8, P = 0.0007), female gender (OR 2.0, P = 0.04), and smoking (OR 2.9, P = 0.02), were significant predictors of any bleeding at 18 months in univariate analyses

  • Multivariable analysis showed that only an INR > 2.6 predicted overall bleeding (OR 19.2, 95% CI 4.3-44.6; P=0.0003).


18-month MACE Specificity

%

P=0.7


Conclusions

In high risk patients implanted with coronary stent, Specificity

long term triple therapy seems to be safe and effective.

Careful monitoring and low target of INR must be provided in these patients

Conclusions


ad